Analysis of the Anticoagulant Market

Novel Oral Agents are Expected to Increase Market Size and Heighten Competition

USD 4,950.00

* Required Fields

USD 4,950.00


Be the first to review this product

The U.S. anticoagulant market is on the verge of a potential major shift in clinical practice, from a market dominated by a single injectable anticoagulant to a highly competitive market dominated by first-in-class novel oral anticoagulants. While these novel oral agents are expected to become standard of care for stroke prevention in atrial fibrillation patients, injectable agents will likely maintain their hold on certain hospital-based critical care applications. This research service covers the U.S. anticoagulant market from 2008 to 2016, with 2010 as the base year. Included are products on the market, products in development, and patient and revenue forecasts. Market challenges, drivers and restraints a

Table of Contents

Analysis of the Anticoagulant Market, U.S. Anticoagulant MarketAnalysis of the U.S. Anticoagulant MarketResearch Service

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.